Table Graph
   

anti-inflammatoty and immuno-therapy - versus potential COVID-19 treatments - for COVID 19 all comers pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.94 [0.85, 1.03]< 142%3 studies (4/-)90.0 %some concernnot evaluable moderatecrucial-
death or transfer to ICU 0.97 [0.50, 1.88]< 10%1 study (1/-)53.6 %NAnot evaluable crucial-
deaths 0.95 [0.87, 1.03]< 123%4 studies (5/-)91.1 %some concernnot evaluable moderatecrucial1
clinical deterioration 1.10 [0.60, 2.01]< 10%2 studies (2/-)37.9 %lownot evaluable highimportant-
clinical improvement 1.05 [0.83, 1.34]> 10%2 studies (2/-)67.0 %lownot evaluable highimportant-
clinical improvement (14-day) 1.33 [0.57, 3.11]> 10%1 study (1/-)74.2 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.04 [0.67, 1.62]> 10%1 study (1/-)57.5 %NAnot evaluable important-
death or ventilation 0.90 [0.81, 0.99]< 10%2 studies (2/-)98.2 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.87 [0.74, 1.02]< 10%1 study (1/-)96.0 %NAnot evaluable important-
radiologic improvement (14-day) 6.48 [1.72, 24.44]> 10%1 study (1/-)99.7 %NAnot evaluable important-
viral clearance 1.78 [1.06, 3.00]> 10%1 study (1/-)98.5 %NAnot evaluable important-
viral clearance (time to event analysis only) 1.78 [1.06, 3.00]> 10%1 study (1/-)98.5 %NAnot evaluable important-
ICU admission 1.00 [0.13, 7.45]< 10%1 study (1/-)50.0 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 1.21 [0.58, 2.53]< 10%1 study (1/-)30.6 %NAnot evaluable important-
adverse events 0.10 [0.03, 0.34]< 10%1 study (1/-)100.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons